

Nisreen M A Okba

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3541730/nisreen-m-a-okba-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

6,140
citations

27
h-index

52
g-index

52
ext. papers

7,906
ext. citations

15.3
avg, IF

6.14
L-index

#	Paper	IF	Citations
47	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021 , 184, 1188-1200.e19	56.2	68
46	A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. <i>Nature Communications</i> , 2021 , 12, 1715	17.4	60
45	A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. <i>European Journal of Immunology</i> , 2021 , 51, 1774-1784	6.1	9
44	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <i>Nature Communications</i> , 2021 , 12, 3189	17.4	76
43	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. <i>Journal of Infectious Diseases</i> , 2021 , 223, 2020-2028	7	16
42	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	27
41	Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
40	Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). <i>Nature Communications</i> , 2021 , 12, 267	17.4	333
39	Susceptibility of rabbits to SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2021 , 10, 1-7	18.9	70
38	A human monoclonal antibody blocking SARS-CoV-2 infection. <i>Nature Communications</i> , 2020 , 11, 2251	17.4	685
37	Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV. <i>Emerging Microbes and Infections</i> , 2020 , 9, 1080-1091	18.9	9
36	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020 , 369, 643-650	33.3	724
35	Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. <i>Emerging Infectious Diseases</i> , 2020 , 26, 1478-1488	10.2	1055
34	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. <i>Nature Communications</i> , 2020 , 11, 3436	17.4	224
33	SARS-CoV-2 is transmitted via contact and via the air between ferrets. <i>Nature Communications</i> , 2020 , 11, 3496	17.4	271
32	Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies. <i>Emerging Infectious Diseases</i> , 2020 , 26, 1024-1027	10.2	13
31	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. <i>Lancet Infectious Diseases</i> , 2020 , 20, 827-838	25.5	74

30	Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. <i>Science Immunology</i> , 2020 , 5,	28	554
29	Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. <i>Science</i> , 2020 , 368, 1012-1015	33.3	596
28	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya. <i>Viruses</i> , 2020 , 12,	6.2	7
27	Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. <i>Emerging Infectious Diseases</i> , 2019 , 25, 1868-1877	10.2	65
26	Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus. <i>Emerging Infectious Diseases</i> , 2019 , 25, 1878-1883	10.2	12
25	Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors. <i>Journal of Virology</i> , 2019 , 93,	6.6	27
24	Zika Virus Infection Induces Elevation of Tissue Factor Production and Apoptosis on Human Umbilical Vein Endothelial Cells. <i>Frontiers in Microbiology</i> , 2019 , 10, 817	5.7	15
23	Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits. <i>Viruses</i> , 2019 , 11,	6.2	8
22	Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. <i>Emerging Microbes and Infections</i> , 2019 , 8, 516-530	18.9	86
21	Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein. <i>Emerging Microbes and Infections</i> , 2019 , 8, 1593-1603	18.9	19
20	MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017. <i>Emerging Infectious Diseases</i> , 2019 , 25, 2333-2335	10.2	15
19	Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. <i>Science Advances</i> , 2018 , 4, eaas9667	14.3	55
18	Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels. <i>One Health</i> , 2018 , 5, 65-68	7.6	30
17	MERS-coronavirus: From discovery to intervention. <i>One Health</i> , 2017 , 3, 11-16	7.6	34
16	Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. <i>Current Opinion in Virology</i> , 2017 , 23, 49-58	7.5	47
15	An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. <i>Science</i> , 2016 , 351, 77-81	33.3	182
14	A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels. <i>International Journal of Infectious Diseases</i> , 2016 , 45, 421-422	10.5	78
13	Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.		3

12	A human monoclonal antibody blocking SARS-CoV-2 infection	53
11	SARS-CoV-2 specific antibody responses in COVID-19 patients	88
10	Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment	27
9	Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants	109
8	Convalescent Plasma for COVID-19. A randomized clinical trial	83
7	Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands	10
6	SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model	16
5	Susceptibility of rabbits to SARS-CoV-2	11
4	Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies	14
3	Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein	9
2	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection	1
1	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination	6